Author/ Professor Chris Trimble Explains Why Reverse Innovation Is “Oxygen,” Not Optional For MNCs: An Interview With PharmAsia News (Part 2 Of 2)
This article was originally published in PharmAsia News
Authors Chris Trimble and Vijay Govindarajan, professors at The Tuck School of Business at Dartmouth, coined the term ‘reverse innovation’ and recently published a book arguing why MNCs need to incorporate RI systemically into their core competitive strategies. Below, Trimble speaks to PharmAsia News on the topic and how pharma companies can relate to it.
You may also be interested in...
New Approaches To Innovation Needed To Reach Globe's Poor At The "Bottom Of The Pyramid" - And To Fend Off Emerging Competitors Around The World
CAMBRIDGE, Mass. - Life science companies looking to provide healthcare solutions to the poorer, "bottom of the pyramid" - a population reaching more than 600 million people in India alone - should focus on business model innovation as much as on innovative products, according to delegates at the U.S.-India Chamber of Commerce biopharmaceutical and healthcare summit in Cambridge, Mass
ACOs have been one of the most hyped innovations in the US health care sector this decade. The buzz may be overdone, but ACOs are now established as a different—and confusing—new customer segment for pharma. How is industry adjusting?
Pharma companies are building long-term value propositions that should appeal to Accountable Care Organizations into some go-to-market strategies for new drugs and to repositioning efforts of already marketed drugs that have hit snags. The rationale might seem straightforward—for example, more convenient dosing that improves compliance and cuts down hospitalization rates--but the nuances can be complex. Moreover, even when their products appear to have compelling cases for value, companies have not by and large made ACOs a distinct target for their commercial operations.